Chinese cancer diagnostics firm SeekIn said Monday that it has received the CE mark for its PanCanSeek Cancer Mutation Detection Kit and now intends to market the test in the European Union and other regions that recognize the designation.

On December 14, 2022, Autobio and Pushkang signed a strategic cooperation agreement in Zhengzhou, and the two sides will again open in-depth cooperation in the field of blood coagulation testing.

Scientists from the National University of Singapore (NUS) have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, this new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood.

Biodesix said Monday that it has been awarded a US Federal Supply Schedule contract for cancer testing of covered patients served by the Veterans Health Administration and Military Health System.

OraSure Technologies announced on Wednesday that it has been awarded an $8.6 million contract from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Roche announced on Tuesday that it is launching three new tests on its molecular Cobas 5800 instrument in countries accepting the CE mark.

Oxford Nanopore Technologies reported on Tuesday morning that its revenues in the first half of 2022 more than doubled year over year, driven by COVID-19 testing.

CorDx said on Wednesday that it has received CE marking for a monkeypox virus antigen test.

Becton Dickinson announced on Monday that it has inked a deal with Accelerate Diagnostics to sell that firm's Accelerate Pheno system and the Accelerate Arc module for antimicrobial susceptibility testing.

Guardant Health and Thermo Fisher Scientific said on Friday that the US Food and Drug Administration has granted premarket approvals for their respective next-generation sequencing assays as companion diagnostics to Enhertu (trastuzumab deruxtecan)